MSCL — Satellos Bioscience Cashflow Statement
0.000.00%
Last trade - 00:00- CA$213.73m
- CA$175.83m
Annual cashflow statement for Satellos Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | fx Final | Final |
| Net Income/Starting Line | -12.4 | -8.7 | -11.8 | -20.5 | -24.9 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 8.72 | 3.39 | 0.75 | 3.01 | 2.75 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.499 | 0.662 | 0.273 | -0.748 | -1.48 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -4.02 | -4.39 | -10.7 | -18.2 | -23.6 |
| Capital Expenditures | -0.006 | -0.003 | -13 | -27.3 | -0.006 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1.39 | 0 | — | 31.9 | -9.41 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 1.39 | -0.003 | -13 | 4.63 | -9.42 |
| Financing Cash Flow Items | 5.33 | 0 | 0.378 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 5.94 | 2.13 | 37.8 | 39 | 2.24 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.31 | -2.26 | 14.9 | 26 | -30.3 |